Advertisement

Atlas of AIDS pp 212-236 | Cite as

Treatment and Prophylaxis of Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy

  • Judith Feinberg

Keywords

Pneumocystis Carinii Pneumonia Cryptococcal Meningitis Mycobacterium Avium Complex Cytomegalovirus Retinitis Multicenter AIDS Cohort Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Phair J, Muñoz A, Detels R, et al.: The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990, 322:161–165.PubMedCrossRefGoogle Scholar
  2. 2.
    Hoover DR, Saah AJ, Baceller H, et al.: Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis: Multicenter AIDS Cohort Study. N Engl J Med 1993, 329:1992–1926.CrossRefGoogle Scholar
  3. 3.
    Conte JE Jr, Hollander H, Golden JA: Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia: A pilot study. Ann Intern Med 1987, 107:495–498.Google Scholar
  4. 4.
    Kovacs JA, Hiementz JW, Macher AM, et al.: Pneumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984, 100:633–641.CrossRefGoogle Scholar
  5. 5.
    Sattler FR, Cowan R, Nielsen DM, Ruskin J: Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A prospective, noncrossover study. Ann Intern Med 1988, 109:280–287.PubMedCrossRefGoogle Scholar
  6. 6.
    Bozzette SA, Sattler FR, Chiu J, et al.: A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1451–1457.PubMedCrossRefGoogle Scholar
  7. 7.
    National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia: Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1500–1504.CrossRefGoogle Scholar
  8. 8.
    Medina I, Mills L, Leoung G, et al: Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Eng J Med 1990, 323:776–782.CrossRefGoogle Scholar
  9. 9.
    Allegra CJ, Kovacs JA, Drake JC, et al.: Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med 1987, 165:926–931.PubMedCrossRefGoogle Scholar
  10. 10.
    Allegra CJ, Chabner BA, Tuazon CH, et al: Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. N Engl J Med 1987, 317:978–985.PubMedCrossRefGoogle Scholar
  11. 11.
    Sattler FR, Frame P, Davis R, et al.: Comparison of trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate-to-severe episodes of Pneumocystis carinii pneumonia in patients with AIDS. J Infect Dis 1994, 170(1): 165–172.PubMedCrossRefGoogle Scholar
  12. 12.
    Hughes WT, Gray VL, Gutteridge WE, et al.: Efficacy of hydroxynaphtho-quinone, 566C80, in experimental Pneumocystis carinii. Antimicrob Agents Chemother 1990, 34:225–228.CrossRefGoogle Scholar
  13. 13.
    Falloon J, Kovacs J, Hughes W, Gray VL, Gutteridge WE, et al: Efficacy of hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii Pneumocystis. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1991, 325:1534–1538.PubMedCrossRefGoogle Scholar
  14. 14.
    Hughes W, Leoung G, Kramer F, et al: Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993, 328:1521–1527.PubMedCrossRefGoogle Scholar
  15. 15.
    Black JR, Feinberg J, Murphy RL, et al.: Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044. Clin Infect Dis 1994, 18:905–913.PubMedCrossRefGoogle Scholar
  16. 16.
    Toma E, Fournier S, Poisson M, et al.: Clindamycin with primaquine for Pneumocystis carinii pneumonia. Lancet 1989, 1:1046–1048.PubMedCrossRefGoogle Scholar
  17. 17.
    Centers for Disease Control and Prevention: USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary. MMWR 1995, 44(RR-8):1–34.Google Scholar
  18. 18.
    Masur H, Feinberg J, et al: Guidelines for prophylaxis of Pneumocystis carinii pneumonia for persons infected with the human immunodeficiency virus. J Acquir Defic Syndr 1993, 6:46–55.Google Scholar
  19. 19.
    Schneider MME, Hoepelman AIM, Eeftinck-Schattenkerk JKM, et al.: A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992,329:1836–1841.CrossRefGoogle Scholar
  20. 20.
    Simonds RJ, Hughes WT, Feinberg J, Navin TR: Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Clin Infec Dis 1995, 21 (suppl 1):S44–S48.CrossRefGoogle Scholar
  21. 21.
    Rozzette SA, Finkelstein DM, Spector SA, et al.: A randomized controlled trial of three anti-Pneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995, 332:693–699.CrossRefGoogle Scholar
  22. 22.
    Leport C, Raffi F, Matheson S, et al.: Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome: Efficacy of long-term therapy. Am J Med 1988, 84:94–100.PubMedCrossRefGoogle Scholar
  23. 23.
    Dannemann B, McCutchan JA, Israelski D, et al.: Treatment of toxoplasmic encephalitis in patients with AIDS: A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992, 116:33–43.PubMedCrossRefGoogle Scholar
  24. 24.
    Katlama C, De Wit S, Guichard A, et al.: A randomized European trial comparing pyrimethamine-clindamycin to pyrimethamine-sulfadiazine in AIDS toxoplasmic encephalitis [abstract 1215]. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992.Google Scholar
  25. 25.
    Girard P-M, Landman R, Gaudebout C, et al: Dapone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993, 328:1514–1520.PubMedCrossRefGoogle Scholar
  26. 26.
    Carr A, Tindall B, Brew BJ, et al: Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992, 117:106–111.PubMedCrossRefGoogle Scholar
  27. 27.
    Mallolas J, Lamora L, Gattell IM, et al: Primary prophylaxis for Pneumocystis carinii pneumonia: A randomized trial comparing cotrimazole, aerosolized pentamidine, and dapsone plus pyrimethamine. AIDS 1993, 7:59–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Leport C, Morlat P, Chene G, et al: Pyrimethamine for primary prophylaxis of toxoplasmosis in HIV patients. A double-blind randomized trial [abstract 36]. Presented at the First National Conference on Human Retroviruses and Related Infections, Washington, DC, Dec 12–16, 1993.Google Scholar
  29. 29.
    Laine L, Dretler RH, Conteas CN, et al: Fluconazole compared with keto-conazole for the treatment of Candida esophagitis in AIDS: A randomized trial. Ann Intern Med 1992, 117:655–660.PubMedCrossRefGoogle Scholar
  30. 30.
    Boken DJ, Swindens S, Rinaldi MC: Fluconazole-resistant Candida albicans in HIV infection [abstract P0-B09–1358]. Presented at the IX International Conference on AIDS, Berlin, 1993.Google Scholar
  31. 31.
    Baily GG, Perry FM, Denning DW, Mandai BR: Fluconazole-resistant candidiasis in an HIV cohort [abstract P0-B09–1375]. Presented at the IX International Conference on AIDS, Berlin, 1993.Google Scholar
  32. 32.
    Bennett JE, Dismukes WE, Duma RJ, et al: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979, 301:126–131.PubMedCrossRefGoogle Scholar
  33. 33.
    Larsen RA, Leal MAE, Chan LS: Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: A randomized trial. Ann Intern Med 1990, 113:183–187.PubMedCrossRefGoogle Scholar
  34. 34.
    Chuck SL, Sande MA: Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989, 321:794–799.PubMedCrossRefGoogle Scholar
  35. 35.
    Saag MS, Powderly WG, Cloud GA, et al: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83–89.PubMedCrossRefGoogle Scholar
  36. 36.
    de Gans J, Portegies P, Tiessens G, et al: Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992, 6:185–190.PubMedCrossRefGoogle Scholar
  37. 37.
    Bozzette SA, Larsen RA, Chiu J, et al: A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:580–584.PubMedCrossRefGoogle Scholar
  38. 38.
    Larsen RA, Bozzette SA, McCutchan JA, et al: Persistent cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med 1989, 111:125–128.PubMedCrossRefGoogle Scholar
  39. 39.
    Powderly WG, Saag MS, Cloud GA, et al: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992, 326:793–798.PubMedCrossRefGoogle Scholar
  40. 40.
    Wheat LJ, Connolly-Stringfield PA, Baker RL, et al: Disseminated histoplasmosis in the acquired immunodeficiency syndrome: Clinical findings, diagnosis and treatment, and review of the literature Medicine 1990, 69:361–374.PubMedGoogle Scholar
  41. 41.
    Wheat LJ, Hafner RE, Ritchie M, Schneider D: Itraconazole is effective treatment for histoplasmosis in AIDS: Prospective multicenter non-comparative trial [abstract 1206]. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992.Google Scholar
  42. 42.
    Wheat J, Hafner R, Wulfsohn M, et al: Prevention of relapse of histoplasmosis with itraconazole in patients with acquired immunodeficiency syndrome. Ann Intern Med 1993, 118:610–616.PubMedCrossRefGoogle Scholar
  43. 43.
    Powderly WG, Finkelstein DM, Feinberg J, et al.: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995, 332:700–705.PubMedCrossRefGoogle Scholar
  44. 44.
    Kaplan JE, Masur H, Holmes KK: USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary. MMWR 1995, 44(RR-8):l-34.Google Scholar
  45. 45.
    Pinner RW, Hajjeh RA, Powderly WG: Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995, 21 (suppl 1):S103–S117.CrossRefGoogle Scholar
  46. 46.
    Spector SA, Weingeist T, Pollard RB, et al: A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS: AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis 1993, 168:557–563.PubMedCrossRefGoogle Scholar
  47. 47.
    Palestine AG, Polis MA, DeSmet MD, et al: A randomized controlled trial of foscarnet in the treatment of CMV retinitis in patients with AIDS. Ann Intern Med 1991, 115:665–673.PubMedCrossRefGoogle Scholar
  48. 48.
    Studies of the Ocular Complications of AIDS Research Group with the AIDS Clinical Trials Group: Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992, 326:213–220.CrossRefGoogle Scholar
  49. 49.
    The Studies of Ocular Complications of AIDS with the AIDS Clinical Trials Group: Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996, 114:23–33.CrossRefGoogle Scholar
  50. 50.
    Lalezari J, Stagg R, Kuppermann B, et al: A phase II/III randomized study of immediate versus deferred cidofovir for the treatment of peripheral CMV retinitis in patients with AIDS [abstract LB 18]. Presented at the Second National Conference on Human Retroviruses and Related Infections. Washington, DC, 1995.Google Scholar
  51. 51.
    Drew WL, Ives D, Lalezari JP, et al: Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995,333:615–620.PubMedCrossRefGoogle Scholar
  52. 52.
    Martin DF, Parks DJ, Mellow SD, et al.: Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: A randomized controlled clinical trial. Arch Ophthalmol 1996, 112:1531–1539.CrossRefGoogle Scholar
  53. 53.
    The Chiron Ganciclovir Implant Study Group: A randomized controlled multicenter clinical trial of a sustained-release intraocular ganciclovir implant in AIDS patients with CMV retinitis [abstract LB16]. Presented at the Second National Conference on Human Retroviruses and Related Infections. Washington, DC, 1995.Google Scholar
  54. 54.
    Spector SA, McKinley GF, Lalezari JP, et al.: Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. New Engl J Med 1996,334:1491–1497.PubMedCrossRefGoogle Scholar
  55. 55.
    Feinberg J, Cooper D, Hurwitz S: Phase III international study of valaci-clovir for cytomegalovirus prophylaxis in patients with advanced HIV disease. Presented at the 11th International Conference on AIDS. Vancouver, BC, 1996.Google Scholar
  56. 56.
    Brosgart CL, Craig C, Hillman D, et al.: A randomized placebo-controlled trial of the safety and efficacy of oral ganciclovir of prophylaxis of CMV retinal and gastrointestinal mucosal disease in HIV-infected individuals with severe immunosuppression [abstract 10]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995.Google Scholar
  57. 57.
    Shinkai M, Spector SA and the ACTG 181 Protocol Team: Quantitation of human cytomegalovirus DNA in plasma by a competitive PCR assay identifies AIDS patients at highest risk for CMV disease [abstract H23]. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994.Google Scholar
  58. 58.
    Griffiths PD, Feinberg J: Detection of cytomegalovirus in samples from patients enrolled in ACTG 204/Glaxo Wellcome 123–014 [abstract]. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.Google Scholar
  59. 59.
    Spector SA, Pilcher M, Lamy P, et al.: PCR of plasma for cytomegalovirus DNA identifies HIV-infected persons most likely to benefit from oral ganciclovir prophylaxis [abstract Th.B.302]. Presented at the XI International Conference on AIDS, Vancouver, BC, 1996.Google Scholar
  60. 60.
    Baldassano V, Dunn JP, Feinberg J, Jabs D: Cytomegalovirus retinitis and low CD4+ T-lymphocyte counts [letter]. N Engl J Med 1995, 333:670.PubMedCrossRefGoogle Scholar
  61. 61.
    Masur H and the Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium complex: Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993, 329:898–904.PubMedCrossRefGoogle Scholar
  62. 62.
    Shafran SD, Singer J, Zarowny DP, et al.: A comparison of two regimens for the treatment of Mycobacterium avium bacteremia in AIDS: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine and ciprofloxacin. N Engl J Med 1996, 335:377–383.PubMedCrossRefGoogle Scholar
  63. 63.
    Nightingale SD, Cameron DW, Gordin FM, et al.: Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993, 329:828–833.PubMedCrossRefGoogle Scholar
  64. 64.
    Pierce M, Crampton S, Henry D, et al.: A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996, 335:384–391.PubMedCrossRefGoogle Scholar
  65. 65.
    Benson CA, Cohn DL, Williams P: A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin vs. rifabutin vs. clarithromycin + rifabutin for prevention of Mycobacterium avium complex disease in HIV+ patients with CD4 counts > cells/μL [abstract 205]. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.Google Scholar
  66. 66.
    Havlir DV, Dube MP, Sattler FR, et al.: Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996, 335:392–398.PubMedCrossRefGoogle Scholar
  67. 67.
    Ostroff SM, Spiegel RA, Feinberg J, et al.: Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1995, 21(suppl 1):S72–S75.CrossRefGoogle Scholar
  68. 68.
    Currier S, Williams PL, Grimes JM, et al.: Incidence rates and risk factors for opportunistic infections in a phase III trial comparing indinavir + ZDV + 3TC to ZDV + 3TC. Presented at the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 1998.Google Scholar
  69. 69.
    Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112–116.PubMedCrossRefGoogle Scholar
  70. 70.
    Freeman WR, Macdonald JC, Torriani FJ, Karavellas: Ophthalmologic manifestation of immunerecovery in AIDS patients on HAART therapy. Presented at the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 1998.Google Scholar
  71. 71.
    O’Sullivan CE, Drew WL, McMullen DJ, et al.: Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J Infect Dis 1999, 180:847–849.PubMedCrossRefGoogle Scholar
  72. 72.
    Lyles RH, Chu C, Mellors JW, et al.: Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study. AIDS 1999, 13:341–349.PubMedCrossRefGoogle Scholar
  73. 73.
    Tural C, Romeu J, Sirera G, et al.: Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998, 177:1080–1083.PubMedCrossRefGoogle Scholar
  74. 74.
    Castagliola D, et al.: Discontinuation of secondary prophylaxis for CMV. Presented at the 12th World Conference on AIDS, 1998.Google Scholar
  75. 75.
    Aberg JA, Yajko DM, Jacobson MA: Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimy-cobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis 1998, 178:1446–1449.PubMedCrossRefGoogle Scholar
  76. 76.
    Deeks SG, Wrin T, Hoh T, et al.: Virologic and immunologic evaluation of structured treatment interruptions (STI) in patients experiencing long-term virologic failure. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000.Google Scholar
  77. 77.
    Sabin C, Devereux H, Clewley G, et al.: Cytomegalovirus (CMV) infection and HIV RNA levels in individuals with hemophilia. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000.Google Scholar
  78. 78.
    Komanduri K, Feinberg J, Hutchins R, et al.: Persistent deficits in cytomegalovirus (CMV)-specific CD4+ T cell responses in HIV-1-infected subjects with relapsing CMV retinitis after successful highly active antiretroviral therapy (HAART). Presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000.Google Scholar

Selected Bibliography

  1. Bartlett JG, Feinberg J: Update on management of opportunistic infections in patients with HIV infection. Infect Dis Clin Pract 1993, 2:233–246.CrossRefGoogle Scholar
  2. Crowe SM, et al: Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991, 4:770.PubMedGoogle Scholar
  3. Girard P-M, Feinberg J: Progress and problems in AIDS-associated opportunistic infections. AIDS 1994, 8(suppl 1):S249–S259.Google Scholar
  4. Kaplan JE, Masur H, Holmes KK: Prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995, 21(suppl 1).CrossRefGoogle Scholar
  5. Kaplan JE, Masur H, Holmes KK: USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary. MMWR 1995, 44(RR-8):1–34.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Judith Feinberg

There are no affiliations available

Personalised recommendations